Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Pfizer › A strong quarter and earnings beat can sometimes give a stock a big boost. But when that doesn't happen, it usually means there are other factors that are weighing on a business and give ...

Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize. Bourla found out at around 9 p.m. that ...

Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

By now, you know that the COVID-19 vaccine is the best way to protect against severe COVID infections and reduce your chances ...

In addition to the removal of boxed warnings, the FDA is also approving two new drugs for menopausal symptoms which include a ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

Research and development expenses for the fiscal quarter ended September 30, 2025 were $2.5 million compared with $4.6 million for the fiscal quarter ended September 30, 2024. The decrease of $2.1 ...